Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | FPR3 | P25089 | 4/20 | 0.39 |
| ▸ | FPR2 | P25090 | 4/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | POLR1A | O95602 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15167554 | 1.00 | KDM4E (0.51) | KDM4EALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL10018786 | 0.93 | KMT2A (0.56) | KDM4EALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL15167264 | 0.87 | KMT2A (0.51) | KDM4EALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL363797 | 0.87 | KMT2A (0.51) | KDM4EALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL15187471 | 0.86 | KMT2A (0.53) | KDM4EALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL15187472 | 0.82 | KMT2A (0.53) | KDM4EALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL20852069 | 0.82 | KDM4E (0.58) | KDM4EALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL19018103 | 0.81 | KMT2A (0.46) | KDM4EALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL15167550 | 0.80 | KMT2A (0.51) | KDM4EALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL10018803 | 0.80 | KMT2A (0.51) | KDM4EALDH1A1LMNAKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130211057-A1 | MOLECULES HAVING COMBINABLE GROUPS | ARKEMA FRANCE (FR) | 2013-08-15 | — | — | US | disclosed |
| EP-2593438-A1 | MOLECULES HAVING COMBINABLE GROUPS | Arkema France (FR) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007685-A1 | MOLECULES HAVING COMBINABLE GROUPS | ARKEMA FRANCE (FR) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211057-A1 | MOLECULES HAVING COMBINABLE GROUPS | NCAPH, NCL, NCAPD2 | KDM4E 3982/4885ALDH1A1 2812/4885LMNA 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.